Mabtech, a Swedish life science tools company specializing in high-quality immunoassays, reagents, and instrumentation, today announced a strategic collaboration with Sai Life Sciences, a leading ...

Pediatric EBGLYSS trial meets endpoints in dermatitis care; Broader immunology portfolio gains attention beyond metabolic ...

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that preclinical data from its IL ...

University of Pittsburgh School of Medicine researchers have developed an early-stage, experimental "living eye drop" that ...

Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating ...

Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In experimental models, human CAR-T cells manufactu ...

Researchers have developed an experimental “living eye drop” that uses naturally occurring eye bacteria to support corneal wound healing.

PITTSBURGH - University of Pittsburgh School of Medicine researchers have developed an early-stage, experimental "living eye drop" that uses naturally ...

Antengene Corporation Limited (Antengene), a leading innovative, commercial-stage global biotech company, and UCB, a global biopharmaceutical company, today announced that they have entered into an ...

Antengene, UCB sign global exclusive license agreement to develop, manufacture and commercialize ATG-201: Hong Kong Friday, March 6, 2026, 14:00 Hrs [IST] Antengene Corporation Li ...

UCB obtains worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseasesDeal ...

With clinical data beginning to emerge, big pharma is signaling its belief that in vivo CAR generation is the next immunotherapy breakthrough.